Developing medical countermeasures: from BioShield to BARDA
Author(s) -
Tucker Jonathan B.
Publication year - 2009
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20299
Subject(s) - legislation , business , government (linguistics) , human services , private sector , preparedness , incentive , government regulation , public administration , public relations , political science , law , philosophy , linguistics , economics , microeconomics , china
Abstract The U.S. Congress passed the Project BioShield Act in 2004 to create market incentives for the private sector to develop medical countermeasures (MCMs) against high‐priority chemical, biological, radiological, and nuclear threats. Two years later, Congress patched recognized gaps in the BioShield legislation by adopting the Pandemic and All‐Hazards Preparedness Act of 2006, which established the Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services (DHHS). BARDA provides financial and managerial support for companies developing MCMs. This article examines U.S. government efforts in the MCM field and prospects for the future. Drug Dev Res 70:224–233, 2009. © 2009 Wiley‐Liss, Inc.